DexTech Medical AB, Invitation to open Annual General Meeting and notice

On Thursday, October 31, 2024, DexTech Medical AB ("DexTech") will hold its Annual General Meeting. Subject to availability, non-shareholders are also welcome to participate without voting rights. At the meeting, the founders, CEO Anders R Holmberg and Medically Responsible Professor Sten Nilsson, among others, will present the company and the clinical situation regarding prostate cancer and multiple myeloma. There will be an opportunity to ask questions to DexTech's Board of Directors and management. Formal notice of the Annual General Meeting is available further down in this press release. Notification for non-shareholders shall be made no later than Tuesday, October 29, 2024, and may be made by e-mail (gosta.lundgren@dextechmedical.com) or in writing to DexTech Medical AB, Annual General Meeting, Box 389, SE-751 06 Uppsala, Sweden. The Annual General Meeting will begin at 10.00 a.m. CET in IVA's Conference Centre, the Royal Swedish Academy of Sciences. The Royal Swedish Academy of Engineering Sciences, Grev Turegatan 16, Stockholm. Admission to the Annual General Meeting will begin at 9.30 a.m. In addition to the above, please note that participation for non-shareholders is subject to formal approval by the Annual General Meeting at the beginning of the Annual General Meeting. For further information Gösta Lundgren – CFO DexTech Medical AB Phone: +46 (0) 70 710 47 88 E-mail: gosta.lundgren@dextechmedical.com DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The lead candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on the Spotlight Stock Market. See below formal notice of the Annual General Meeting WELCOME TO THE ANNUAL GENERAL MEETING 2024 I DEXTECH MEDICAL AB (publ) Dextech Medical AB's shareholders are welcome to participate in the Annual General Meeting that will be held Thursday 31 October 2024 at 10.00 a.m. at IVA's Conference Centre, Kungl. The Royal Swedish Academy of Engineering Sciences, Grev Turegatan 16, Stockholm. Admission to the Annual General Meeting will begin at 9.30 a.m. Subject to availability and that the meeting so resolves, non-shareholders are also welcome to participate in the meeting without voting rights. Registration and registration Shareholders who wish to participate in the Annual General Meeting must: • be entered in the share register maintained by Euroclear Sweden AB on Wednesday 23 October 2024, and • notify the company of their intention to participate no later than Tuesday, October 29, 2024. Notice of attendance may be made by e-mail (gosta.lundgren@dextechmedical.com) or in writing to Dextech Medical AB, Annual General Meeting, Box 389, SE-751 06 Uppsala, Sweden. The notification must state your full name, personal identity number or corporate identity number, shareholding, address, daytime telephone number and, if applicable, information about a deputy or assistant (maximum 2). The notification must be accompanied, where applicable, by powers of attorney, registration certificate and other documents of authority. The Annual General Meeting will be held in Swedish. Nominee-registered shares A person whose shares are registered in the name of a nominee must, in order to be entitled to participate in the meeting, have the shares registered in their own name through the agency of a nominee, so that they are registered in the share register maintained by Euroclear Sweden AB as of the record date on Wednesday, October 23, 2024. Such registration may be temporary (so-called voting rights registration). Shareholders who wish to register the shares in their own name must, in accordance with the respective nominee's procedures, request that the nominee makes such voting rights registration. Voting rights registration that has been requested by shareholders in such time that the registration has been made by the relevant nominee no later than Wednesday 23 October 2024 will be taken into account in the preparation of the share register. Agents, etc. If a shareholder is to be represented by a proxy, the proxy must have a written, dated and signed power of attorney for the meeting by the shareholder. The power of attorney may not be older than one year, unless a longer period of validity (but not more than five years) has been stated on the power of attorney. If the power of attorney has been issued by a legal entity, the representative must also bring the current certificate of registration or equivalent authorization documents for the legal entity. To facilitate entry, a copy of the power of attorney and other authorization documents should be attached to the notification to the meeting. Proxy forms are available on the company's website www.dextechmedical.com and are sent by mail to shareholders who contact the company and state their address. Agenda   1.           Election of Chairman of the Meeting.   2.           Preparation and approval of the voting list.   3.                          Approval for non-shareholders to attend the meeting.   4.           Approval of the agenda.   5.           Election of one or two persons to verify the minutes together with the chairman.   6.           Determination of whether the meeting has been duly convened.   7.           The CEO's speech and a presentation of the clinical situation by Professor Sten Nilsson as well as questions from the shareholders to the company's Board of Directors and management.   8.           Presentation of the annual report and auditor's report for the financial year 2023/2024.   9.           Resolution on adoption of the income statement and balance sheet. 10.          Resolution on appropriation of the company's profit or loss in accordance with the adopted balance sheet. 11.          Resolution on discharge from liability for the members of the Board of Directors and the CEO. 12.         Determination of the number of Board members, deputy Board members and, where applicable, of the number of auditors or auditing firm and any deputy auditors. 13.          Determination of fees to be paid to the Board of Directors and the auditors. 14.          Election of the Board of Directors, Chairman of the Board and any deputies. 15.          Election of auditors or auditing firm and any deputy auditors. 16.          Other matters that are to be dealt with at the meeting in accordance with the Swedish Companies Act or                Articles of Association. 17. Closing of the meeting. Proposals for resolutions in brief Determination of the number of members of the Board of Directors and deputy members of the Board of Directors (item 12) According to the Articles of Association, the Board of Directors shall consist of a minimum of three and a maximum of seven members with a maximum of two deputies. Shareholders representing just over 60% of the total number of shares in the company have proposed that the number of Board members shall be five members and that no deputies be elected. Election of the Board of Directors (item 14) Shareholders representing more than 60% of the total number of shares in the company have proposed that the following persons be elected as members of the Board of Directors: Re-election of Andreas Segerros, Peter Benson, Per-Olof Asplund, Rolf Eriksson and Svante Wadman, with Andreas Segerros as Chairman. Election of auditor (item 15) Shareholders representing more than 60% of the total number of shares in the company have proposed re-election of KPMG AB as auditor. The Board's proposal Appropriation of the Company's result (item 10) The funds at the disposal of the Annual General Meeting consist of profit for the year of SEK -4,705,567, the Company's share premium reserve of SEK 105,195,317 and the Company's retained profit of SEK -82,621,757, a total of SEK 17,867,993. The Board of Directors proposes that the funds at the disposal of the Annual General Meeting of SEK 17,867,993 be carried forward. Shares and votes There are a total of 18,485,857 shares and an equal number of votes in the company. Documents The Annual Report and the Auditor's Report are available on the company's website www.dextechmedical.com. __________________________ Stockholm, September 2024 BOARD